Healthcare [ 5/13 ] | Biotechnology [ 38/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 13, 23 | -0.63 Increased by +27.59% | -0.49 Decreased by -28.57% |
| Aug 7, 23 | -0.45 Increased by +47.67% | -0.49 Increased by +8.16% |
| May 11, 23 | -0.4 Increased by +66.1% | -0.55 Increased by +27.27% |
| Mar 22, 23 | -0.72 Increased by +93.45% | -0.71 Decreased by -1.41% |
| Nov 10, 22 | -0.87 Decreased by -42.62% | -0.92 Increased by +5.43% |
| Aug 9, 22 | -0.86 Increased by +31.75% | -1.01 Increased by +14.85% |
| May 12, 22 | -1.18 Increased by +18.06% | -0.73 Decreased by -61.64% |
| Mar 10, 22 | -11 Decreased by -316.67% | -0.66 Decreased by -1.57 K% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0 Decreased by N/A% | -17.73 M Decreased by -58.69% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0 Decreased by N/A% | -12.57 M Decreased by -15.95% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0 Decreased by N/A% | -8.88 M Increased by +41.61% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0 Decreased by N/A% | -12.24 M Decreased by -28.92% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0 Decreased by N/A% | -11.17 M Decreased by -41.93% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0 Decreased by N/A% | -10.84 M Decreased by -45.15% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by N/A% | -15.21 M Increased by +91.06% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0 Decreased by N/A% | -9.49 M Decreased by -5.71% | Decreased by N/A% Decreased by N/A% |
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.